NDC product
Potassium Phosphates
NDC 0409-0032 · Hospira, Inc.
Key facts
| Product NDC | 0409-0032 |
|---|---|
| Proprietary name | Potassium Phosphates |
| Nonproprietary name | potassium phosphates |
| Substances | MONOBASIC POTASSIUM PHOSPHATE, DIBASIC POTASSIUM PHOSPHATE |
| Dosage form | INJECTION, SOLUTION, CONCENTRATE |
| Route | INTRAVENOUS |
| Labeler | Hospira, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA217459 |
| Pharmacologic classes | Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Osmotic Activity [MoA], Osmotic Laxative [EPC], Potassium Compounds [CS], Potassium Salt [EPC] |
| Marketing start | Sep 29, 2025 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: